Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

被引：12

作者：

Yu, Ya-Yen ^{[1
,2
]}

Tsao, Shih-Ming ^{[3
,4
]}

Yang, Wen-Ta ^{[5
]}

Huang, Wei-Chang ^{[6
,7
,8
,9
]}

Lin, Ching-Hsiung ^{[10
]}

Chen, Wei-Wen ^{[11
]}

Yang, Shun-Fa ^{[1
,12
]}

Chiou, Hui-Ling ^{[13
,14
]}

Huang, Yi-Wen ^{[1
,11
]}

机构：

[1] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan

[2] Changhua Hosp, Dept Clin Lab, Changhua 513, Taiwan

[3] Chung Shan Med Univ Hosp, Div Chest, Dept Internal Med, Taichung 402, Taiwan

[4] Chung Shan Med Univ, Inst Biochem Microbiol & Immunol, Taichung 402, Taiwan

[5] Minist Hlth & Welf, Taichung Hosp, Dept Internal Med, Taichung 403, Taiwan

[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung 407, Taiwan

[7] Jen Teh Jr Coll Med Nursing & Management, Dept Med Technol, Miaoli 356, Taiwan

[8] Natl Chung Hsing Univ, Dept Life Sci, Taichung 402, Taiwan

[9] Tunghai Univ, Dept Ind Engn & Enterprise Informat, Taichung 407, Taiwan

[10] Changhua Christian Hosp, Div Chest, Changhua 500, Taiwan

[11] Changhua Hosp, Dept Hlth, Pulm & Crit Care Unit, Changhua 500, Taiwan

[12] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan

[13] Chung Shan Med Univ, Sch Med Lab & Biotechnol, Taichung 402, Taiwan

[14] Chung Shan Med Univ Hosp, Dept Clin Lab, Taichung 402, Taiwan

来源：

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH | 2020年 / 17卷 / 01期

关键词：

drug metabolic enzymes; polymorphism; latent tuberculosis; adverse drug reaction; INDUCED HEPATOTOXICITY; PHARMACOGENOMICS; RIFABUTIN; RIFAMPIN; ISOFORMS; 3A4;

D O I：

10.3390/ijerph17010210

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015-4.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022-2.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250-2.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen.

引用

页数：9

共 31 条

[1] Update on rifampin, rifabutin, and rifapentine drug interactions [J].

Baciewicz, Anne M. ;

Chrisman, Cary R. ;

Finch, Christopher K. ;

Self, Timothy H. .

CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (01) :1-12

[2] Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI [J].

Bliven-Sizemore, E. E. ;

Sterling, T. R. ;

Shang, N. ;

Benator, D. ;

Schwartzman, K. ;

Reves, R. ;

Drobeniuc, J. ;

Bock, N. ;

Villarino, M. E. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (09) :1039-1044

[3] A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment [J].

Bock, NN ;

Sterling, TR ;

Hamilton, CD ;

Pachucki, C ;

Wang, YC ;

Conwell, DS ;

Mosher, A ;

Samuels, M ;

Vernon, A .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (11) :1526-1530

[4] Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine [J].

Brooks, Kristina M. ;

George, Jomy M. ;

Pau, Alice K. ;

Rupert, Adam ;

Mehaffy, Carolina ;

De, Prithwiraj ;

Dobos, Karen M. ;

Kellogg, Anela ;

McLaughlin, Mary ;

McManus, Maryellen ;

Alfaro, Raul M. ;

Hadigan, Colleen ;

Kovacs, Joseph A. ;

Kumar, Parag .

CLINICAL INFECTIOUS DISEASES, 2018, 67 (02) :193-201

[5] High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection [J].

Cynamon, MH ;

Zhang, Y ;

Harpster, T ;

Cheng, S ;

DeStefano, MS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) :2922-2924

[6] Pharmacogenomics of adverse drug reactions [J].

Daly, Ann K. .

GENOME MEDICINE, 2013, 5

[7] Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A [J].

Desta, Z ;

Soukhova, NV ;

Flockhart, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :382-392

[8] Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study [J].

Doan, Tan N. ;

Fox, Greg J. ;

Meehan, Michael T. ;

Scott, Nick ;

Ragonnet, Romain ;

Viney, Kerri ;

Trauer, James M. ;

McBryde, Emma S. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (01) :218-227

[9] Daily Rifapentine for Treatment of Pulmonary Tuberculosis A Randomized, Dose-Ranging Trial [J].

Dorman, Susan E. ;

Savic, Radojka M. ;

Goldberg, Stefan ;

Stout, Jason E. ;

Schluger, Neil ;

Muzanyi, Grace ;

Johnson, John L. ;

Nahid, Payam ;

Hecker, Emily J. ;

Heilig, Charles M. ;

Bozeman, Lorna ;

Feng, Pei-Jean I. ;

Moro, Ruth N. ;

MacKenzie, William ;

Dooley, Kelly E. ;

Nuermberger, Eric L. ;

Vernon, Andrew ;

Weiner, Marc .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (03) :333-343

[10] Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].

Dye, C ;

Scheele, S ;

Dolin, P ;

Pathania, V ;

Raviglione, RC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686

← 1 2 3 4 →